Search alternatives:
patient decrease » point decrease (Expand Search), transient decrease (Expand Search), largest decrease (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
e decrease » we decrease (Expand Search), _ decrease (Expand Search), a decrease (Expand Search)
_ patient » _ patients (Expand Search)
Showing 1 - 20 results of 16,228 for search '(((( a ((e decrease) OR (mean decrease)) ) OR ( _ patient decrease ))) OR ( _ large decrease ))', query time: 0.71s Refine Results
  1. 1
    Maximum IFN concentrations are decreased in severe patients.

    Maximum IFN concentrations are decreased in severe patients. by Sonia T. Gazeau (21512764)

    Published 2025
    Save to List
    Saved in:
  2. 2
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 3
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 4
    Loss of Vps34 is associated with decreased eTreg survival but intact activation.

    Loss of Vps34 is associated with decreased eTreg survival but intact activation. by Erienne G. Norton (9612079)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 5
    Experimental validation revealed that ACADSB and ACADM decreased in patients with UC.

    Experimental validation revealed that ACADSB and ACADM decreased in patients with UC. by Hongliang Chen (538815)

    Published 2025
    Save to List
    Saved in:
  6. 6
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 7
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 8
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 9
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 10
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Overview of the six original ACTIV-3/TICO trials.

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    Line graph showing the increase or decrease in the average number of bee swarms caught over the past three years (Mean 

    Line graph showing the increase or decrease in the average number of bee swarms caught over the past three years (Mean  by Beatrice T. Nganso (4114768)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection.

    Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. by Ryan J. Treves (13527735)

    Published 2025
    Save to List
    Saved in:

Search Tools: